Author

E. Porpiglia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:flow cytometry· 2 Organism:human· 2 Approach:statistical model· 2 Approach:deep learning· 1

Frequent Co-Authors

H. M. Blau· 2 shared V. D. Gonzalez· 2 shared A. De Morree· 1 shared A. Delgado-Gonzalez· 1 shared A. G. Henssen· 1 shared A. Gentles· 1 shared A. J. De Micheli· 1 shared A. Trejo· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

H. M. Blau

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Elevated CD47 is a hallmark of dysfunctional aged muscle stem cells that can be targeted to augment regeneration

E. Porpiglia, T. Mai, P. Kraft, C. A. Holbrook, A. De Morree, V. D. Gonzalez, K. Hilgendorf, L. Fresard, A. Trejo, S. Bhimaraju, P. K. Jackson, W. J. Fantl, H. M. Blau

This study identifies elevated CD47 in aged muscle stem cells as a marker of dysfunction and shows that targeting CD47 improves regeneration in aged mice.

bioRxiv · Apr 29, 2022Cell Biology

Single-cell mapping of tumor heterogeneity in pediatric rhabdomyosarcoma reveals developmental signatures with therapeutic relevance

S. G. Danielli, E. Porpiglia, A. J. De Micheli, N. Navarro, M. J. Zellinger, I. Bechtold, S. Kisele, L. Volken, J. G. Marques, S. Kasper, P. K. Bode, A. G. Henssen, D. Gürgen, J. Roma, P. Bühlmann, , B. W. Schäfer

This study maps tumor heterogeneity in pediatric rhabdomyosarcoma using single-cell data, revealing developmental signatures and identifying the RAS pathway as a therapeutic target.

bioRxiv · Apr 20, 2022 · PreprintCancer Biology

High-Grade Serous Ovarian Tumor Cells Modulate NK Cell Function to Create an Immune-Tolerant Microenvironment

V. D. Gonzalez, Y.-W. Huang, S.-Y. Chen, A. Delgado-Gonzalez, K. Donoso, A. Gentles, K. Sachs, E. Porpiglia, W. Fantl

This study identifies CD9 as a novel therapeutic target in high-grade serous ovarian cancer by showing tumor cells modulate NK cell function through trogocytosis.

bioRxiv · Nov 20, 2020Immunology